openPR Logo
Press release

6th International Conference on HIV/AIDS, STDs and STIs

04-09-2018 03:45 PM CET | Health & Medicine

Press release from: Conference Series LLC Ltd

HIV AIDS Conferences | 70K Visitors | STD Events | Meetings | USA | Europe | Middle East | Aisa | 2018

HIV AIDS Conferences | 70K Visitors | STD Events | Meetings | USA | Europe | Middle East | Aisa | 2018

6th International Conference on HIV/AIDS, STDs and STIs is exclusively designed for immunologists & virologist, physicians, nurses/nurse practitioners, pharmacists, psychologists, behavioral researchers, Healthcare professionals, social scientists, epidemiologists, social workers, AIDS service organization (ASO) staff, students, Researchers, Academicians, Practitioners, Early Career Scholars, students along with Industries and others engaged in endeavors related to STD AIDS research and business.
As HIV/AIDS is an alarming concern throughout the world, STD AIDS 2018 will mainly focus on issues like Primary HIV Infection, Transmission and Eradication Issues apart from this HIV Co-infection, HIV Current pharmaceutical design
As the premier event, we have developed a program with your interests in mind. We have not only increased the number of opportunities for you to network with colleagues from across the world but also introduced more focused sessions that will feature cutting-edge presentations, special panel discussions, and livelier interaction with industry leaders and experts.

Vinay Jetti
1- 702-508-5200
hiv-stds@immunologyconferences.org

San Francisco, USA

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 6th International Conference on HIV/AIDS, STDs and STIs here

News-ID: 1007789 • Views:

More Releases for HIV

HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792 This latest report researches the industry structure, sales, revenue,
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways